Investing.com - Biomarin Pharma (NASDAQ:BMRN) reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $4.01 on revenue of $476.8M. Analysts polled by Investing.com anticipated EPS of $-0.11 on revenue of $454.64M.
Biomarin Pharma shares are up 37.89% from the beginning of the year and are trading at $75.09 , down-from-52-week-high.They are broadly in line with the Nasdaq 100 which is up 38.3% from the start of the year.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by J&J on Tuesday, October 13, 2020, who reported EPS of $2.2 on revenue of $21.08B, compared to forecasts EPS of $1.98 on revenue of $20.2B.
Thermo Fisher Scientific had beat expectations on Wednesday, October 21, 2020 with third quarter EPS of $5.63 on revenue of $8.52B, compared to forecast for EPS of $4.33 on revenue of $7.65B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar